Document is current
Any future updates will be listed below
-
Authors
Renner, Tyler M.
Stuible, Matthew
Cass, Brian
Perret, Sylvie
Guimond, Julie
Lord-Dufour, Simon
McCluskie, Michael J.
Durocher, Yves
Akache, Bassel
-
Funding
Funding for this research was provided by:
National Research Council Canada
Québec Consortium for Drug Discovery
- License Information
-
More Information
Article History
Received: 23 July 2024
Accepted: 19 October 2024
First Online: 21 November 2024
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests: Y.D. is an inventor of a patent application related to the SmT1 antigen (publication number 20230174591). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: Mice were maintained at the small animal facility of the National Research Council (NRC) Canada in accordance with the guidelines of the Canadian Council on Animal Care. All procedures performed on animals in this study were approved by our Institutional Review Board (NRC Human Health Therapeutics Animal Care Committee) and covered under animal use protocol 2020.10. All experiments were carried out in accordance with the ARRIVE guidelines.
